KEYNOTE-048 has broken new ground. What comes next in HNSCC?
KEYNOTE-048 has made headlines in HNSCC. Could these data for Keytruda transform the first-line treatment of recurrent/metastatic disease? KOLs delve into the details of these findings, including potential implications for Opdivo/Yervoy and the CheckMate-651 trial. Curative settings are also fast becoming a key focus for clinical development of immune checkpoint inhibitors; but how promising is this opportunity and how do the experts rate the prospects for Merck & Co., BMS, Roche, AstraZeneca and Merck Group/Pfizer to capture this space? Furthermore, with multiple therapies demonstrating novel mechanisms of action in the pipeline, such as TT10, danvatirsen, M7824 and olaparib, the KOLs provide insight on their potential to succeed in an increasing complex landscape. In this report, twelve KOLs offer candid insights on three marketed and nine Phase II/III therapies, as well as early development programmes.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“Almost everybody wants to use pembrolizumab upfront and start testing for that ahead of the FDA approval if it was possible. We also think it’s a much better option than EXTREME due to its great tolerability. There’s a tremendous amount of enthusiasm.”
US Key Opinion Leader
“You’re going to see them [PD-1/L1 inhibitors] integrated into attempts to cure. There will be neoadjuvant approaches, combinations with radiation in a definitive setting, combinations in the definitive and adjuvant setting. I think you'll see multiple of those be positive and these agents moving to curative settings and therefore not having play in the metastatic/recurrent setting.”
US Key Opinion Leader
Marketed Therapies
Pipeline Therapies
Phase II Therapies
KOLs from North America
KOLs from Europe
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved